Srinivas Raghavan Viswanathan

This study identifies fusion-driven oncogenic programs in translocation renal cell carcinoma (tRCC) that shape an immunosuppressive tumor microenvironment, explaining its reduced immunotherapy response.

This paper identifies a bifunctional small molecule that can induce both transactivation and repression of gene expression depending on cellular context.

This paper detects and monitors translocation renal cell carcinoma (tRCC) using plasma cell-free epigenomic profiling, achieving high accuracy in distinguishing tRCC from other cancers and healthy controls.

The paper identifies CDK9 inhibition as a therapeutic strategy for translocation renal cell carcinoma through phenotypic screening and mechanistic analysis.

This study identifies TFE3 fusions driving OXPHOS in tRCC and reveals EGLN1 inhibition as a therapeutic target.

This study uses machine learning to infer gene dependencies from tumor transcriptomes, identifying cancer vulnerabilities in rare cancers without experimental screening.

The paper identifies epigenomic signatures in sarcomatoid renal cell carcinoma (sRCC) that predict response to immune checkpoint inhibitors and are detectable in plasma, enabling non-invasive diagnosis.

This study identifies distinct structural variation patterns in prostate cancer across disease states, defining clinically actionable subgroups based on whole genome profiling.